Opiate receptor-like 1 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||
Symbols | OPRL1; KOR-3; MGC34578; NOCIR; OOR; ORL1 | ||||||||||||
External IDs | OMIM: 602548 MGI: 97440 HomoloGene: 22609 IUPHAR: NOP GeneCards: OPRL1 Gene | ||||||||||||
|
|||||||||||||
Orthologs | |||||||||||||
Species | Human | Mouse | |||||||||||
Entrez | 4987 | 18389 | |||||||||||
Ensembl | ENSG00000125510 | ENSMUSG00000027584 | |||||||||||
UniProt | P41146 | Q542U1 | |||||||||||
RefSeq (mRNA) | NM_000913.4 | NM_011012.4 | |||||||||||
RefSeq (protein) | NP_000904.1 | NP_035142.1 | |||||||||||
Location (UCSC) | Chr 20: 62.71 – 62.73 Mb |
Chr 2: 181.45 – 181.46 Mb |
|||||||||||
PubMed search | [1] | [2] |
The nociceptin receptor or NOP also known as the orphanin FQ receptor or kappa-type 3 opioid receptor is a protein that in humans is encoded by the OPRL1 (opioid receptor-like 1) gene.[1] The nociceptin receptor is a G protein-coupled receptor whose natural ligand is known as nociceptin or orphanin FQ, a 17 amino acid neuropeptide.[2] This receptor is involved in the regulation of numerous brain activities, particularly instinctive and emotional behaviors.[3]
Contents |
Nociceptin is thought to be an endogenous antagonist of dopamine transport that may act either directly on dopamine or by inhibiting GABA to affect dopamine levels.[4] Within the central nervous system its action can be either similar or opposite to those of opioids depending on their location.[5] It controls a wide range of biological functions ranging from nociception to food intake, from memory processes to cardiovascular and renal functions, from spontaneous locomotor activity to gastrointestinal motility, from anxiety to the control of neurotransmitter release at peripheral and central sites.[5]
Several commonly used opioid drugs including etorphine and buprenorphine have been demonstrated to bind to nociceptin receptors, but this binding is relatively insignificant compared to their activity at other opioid receptors. More recently a range of selective ligands for ORL-1 have been developed, which show little or no affinity to other opioid receptors and so allow ORL-1 mediated responses to be studied in isolation.
ORL 1 agonists are being studied as treatments for heart failure and migraine[6] while nociceptin antagonists such as JTC-801 may have analgesic[7] and antidepressant qualities.[8]
The novel drug buprenorphine is a partial agonist at ORL 1 receptors while its metabolite norbuprenorphine is a full agonist at these receptors.[9]
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
|